Best Time to Start Induction in Term Pregnancies with Misoprostol. Evaluate Early Vs Late Induction and the Mode of Delivery

Download Article

DOI: 10.21522./TAJMHR.2016.05.01.Art019

Authors : Sandrine Phipps

Abstract:

The magic drug/tablet /pill (Misoprostol/ Cytotec) that is used mostly in the Caribbean islands for induction has increased drastically, fifty 50 mcg makes wonders in term pregnancy 37weeks – 41 weeks. Most induction should start early as possible for a more favourable outcome (e.g. 6am) Statistics shown that early induction and closely monitoring plays a vital role for a better delivery decision for mother and her unborn child. It saves time for the health care workers to manage than via an emergency.  After misoprostol is inserted, the woman would have to lay for 2 two hours in the supine position and have pre and post ctg (cardiotocography) done. Given that the process takes a few minutes to insert usually 30 minutes to 1 hour if effective, the patient should report pain or some sort of tightening. The procedure (insertion of misoprostol) can be done about 2-3 times if not effective, the management should be reviewed by the attending ob./gyn and the nurse midwife. Labour of induction is frequently indicated in women with an unfavourable cervix (bishop score <=4), with up to half of all induced labour requiring cervical ripening, prostaglandins have been utilized to increase induction success and achieve vaginal delivery. Has been used off label for over thirty years as a labour induction agent. The challenge is to provide this medication with the correct dosing for this induction and with the ability to discontinue the medication if needed, all while ensuring essential maternal and neonatal safety.

References:

[1].   Gaskin, I. M., 2013, Cytotec and the FDA. Midwifery Today with International Midwife, (107), 8-14.

[2].   Stephenson, M.L., & Wing, D.A., 2015, Misoprostol for induction of labor. Seminars in Perinatology, 39(6), 459-462.

[3].   Wing, D. A., 2002, A benefit-risk assessment of misoprostol for cervical ripening and labour induction. Drug safety, 25 (9), 665-676.

[4].   King, V., Pilliod, R., & little, A., 2010. Rapid review: Elective induction of labor. Portland: Center for evidence – based policy.

[5].   Blanchard, K., Clark, S., Winikoff, B., Gaines, G., Kalani, G., Shannon, C., 2002, Misoprostol for women’s health: A review. Obstetrics and Gynecology, 99:316-332.

[6].   Mozurkewich, E., Chilimigras, J., Koepe, E., Keeton, K., & King, V. J., 2009, Indications for induction of labour: A best- evidence review. BJOG, 116(5), 626-636.

[7].   Kolderup, L., Grullon, K., Safford, K., & Kilpatrick, S. J., 1999. Misoprostol is more efficacious for labour induction than prostaglandin E2, but is it associated with more risk? American Journal of Obstetrics and Gynecology, 180 (6 Pt 1), 1543-1550.

[8].   Kerr, R., Kumar, N., Williams, M. J., et al., 2021, Low – dose oral misoprostol for induction of labour. Cochrane Database Syst Rev, 6(6), CD014484. Doi:10.1002/14651858.CD014484 [PubMed 34155622].

[9].   Kumar, N., Haas, D. M., Weeks, A. D., 2021, Misoprostol for labour induction. Best Pract Res Clin Obstet Gynaecol, 77:53-63. Doi:10.1016/j.bpobgyn.09.003[PubMed 34607746].

[10].  Dadashaliha, M., Fallah, S., Mirzadeh, M., 2021, Labour induction with randomized comparison of cervical, oral, and intravaginal misoprostol. BMC Pregnancy childbirth. Oct 27;21(1): 721. Doi:10.1186/s12884-021-04196-4.

[11].  Alfirevic, Z., Aflaifel, N., Weeks. A., 2014, Oral misoprostol for induction of labour. Cochrane Database Syst Rev, 201(6), CD001338. Doi:10.1002/14651858.CD001338. pub 3[PubMed24924489].

[12].  Amini, M., Wide-Swensson, D., Herbst, A., 2022, Sublingual misoprostol vs oral misoprostol solution for induction of labour: a retrospective study. Front Surg.; 9:968372. Doi:10.1097/AOG.0000000000004082[PubMed 32804884].

[13].  Berghella, V., Bellussi, F., Schoen, C. N., 2020, Evidence-based labour management: induction of labour (part 2) Am J Obstet Gynecol MFM, 2(3): 1001136. Doi: 10.1016/j.ajogmf.2020.100136[PubMed].

[14].  Tang, O. S., Gemzell-Danielsson, K., Ho, P. C., 2007, Misoprostol :pharmacokinetic profiles, effects on the uterus and side effects. Int J Gynaecol Obstet, 99(2):S160-S167. Doi:10. 1016/j.ijgo.2007.09.004[PubMed 17963768].

[15].  Leduc, D., Senikas, V., Lalonde, A. B., 2018, No 235- active management of the third stage of labour: prevention and treatment of post-partum hemorrhage. J Obstet Gynaecol Can, 40(12):e 841-e855. Doi:10.1016/j.jogc.2018.09.024[PubMed 30527079].

[16].  Morris, J. L., Winikoff, B., Dabash, R., et al., 2017, FIGO’s updated recommendations for misoprostol used alone in gynecology and obstetrics. Int J Gynaecol Obstet, 138(3):363-366.Doi:10.1002/ijgo. 1218[PubMed 28643396].

[17].  Robinson, D., Campbell, K., Hobson, S. R., Mac Donald, W. K., Sawchuck, D., Wagner, B., 2023, Guideline no.432c: induction of labour. J Obstet Gynaecol Can, 45 (1):70-77.63. Doi:10.1016/j.jogc.2022.11.009[PubMed].

[18].  Tang, J., Kapp, N., Dragoman, M., et al., 2013, WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet, 121 (2):186-189.

[19].  Muzonzini, G., Hofmeyr, G. J., 2004, Buccal or sublingual misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev.2004; 2004 (4):CD 004221. Doi: 10.1002/14651858.Cd004221.pub2[PubMed 15495088].

[20].  Simpson, K. R., 2020, Cervical ripening and labour induction and augmentation,5th edition. Nurs Women Health, 24(4):S1- S41. Doi:10.1016/j.nwh.2020.04.005[PubMed 32778395].

[21].  Haas, D. M., Daggy, J., Flannery, K. M., et al., 2019, A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labour induction at term ( the IMPROVE trial): a triple- masked randomized controlled trial. Am J Obstet Gynecol, 221 (3):259.e1-259.e16. Doi:10.1016/j.ajog.2019.04.037[PubMed 31075246].